Literature DB >> 24493262

Muscle dysfunction in hypertrophic cardiomyopathy: what is needed to move to translation?

Corrado Poggesi1, Carolyn Y Ho.   

Abstract

Hypertrophic cardiomyopathy (HCM) is caused by mutations in sarcomere genes. As such, HCM provides remarkable opportunities to study how changes to the heart's molecular motor apparatus may influence cardiac structure and function. Although the genetic basis of HCM is well-described, there is much more limited understanding of the precise consequences of sarcomere mutations--how they remodel the heart, and how these changes lead to the dramatic clinical consequences associated with HCM. More precise characterization of the mechanisms leading from sarcomere mutation to altered cardiac muscle function is critical to gain insight into fundamental disease biology and phenotypic evolution. Such knowledge will help foster development of novel treatment strategies aimed at correcting and preventing disease development in HCM.

Entities:  

Mesh:

Year:  2014        PMID: 24493262      PMCID: PMC3982612          DOI: 10.1007/s10974-014-9374-0

Source DB:  PubMed          Journal:  J Muscle Res Cell Motil        ISSN: 0142-4319            Impact factor:   2.698


  67 in total

Review 1.  Invited Review: pathophysiology of cardiac muscle contraction and relaxation as a result of alterations in thin filament regulation.

Authors:  O M Hernandez; P R Housmans; J D Potter
Journal:  J Appl Physiol (1985)       Date:  2001-03

2.  Myofilament Ca sensitization increases cytosolic Ca binding affinity, alters intracellular Ca homeostasis, and causes pause-dependent Ca-triggered arrhythmia.

Authors:  Tilmann Schober; Sabine Huke; Raghav Venkataraman; Oleksiy Gryshchenko; Dmytro Kryshtal; Hyun Seok Hwang; Franz J Baudenbacher; Björn C Knollmann
Journal:  Circ Res       Date:  2012-05-29       Impact factor: 17.367

3.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.

Authors:  H Niimura; L L Bachinski; S Sangwatanaroj; H Watkins; A E Chudley; W McKenna; A Kristinsson; R Roberts; M Sole; B J Maron; J G Seidman; C E Seidman
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

4.  Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho; Begoña López; Otavio R Coelho-Filho; Neal K Lakdawala; Allison L Cirino; Petr Jarolim; Raymond Kwong; Arantxa González; Steven D Colan; J G Seidman; Javier Díez; Christine E Seidman
Journal:  N Engl J Med       Date:  2010-08-05       Impact factor: 91.245

5.  T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.

Authors:  Carolyn Y Ho; Siddique A Abbasi; Tomas G Neilan; Ravi V Shah; Yucheng Chen; Bobak Heydari; Allison L Cirino; Neal K Lakdawala; E John Orav; Arantxa González; Begoña López; Javier Díez; Michael Jerosch-Herold; Raymond Y Kwong
Journal:  Circ Cardiovasc Imaging       Date:  2013-04-02       Impact factor: 7.792

6.  Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy.

Authors:  O Roopnarine; L A Leinwand
Journal:  Biophys J       Date:  1998-12       Impact factor: 4.033

Review 7.  Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications cardiomyopathies: therapeutics based on molecular phenotype.

Authors:  Houman Ashrafian; Hugh Watkins
Journal:  J Am Coll Cardiol       Date:  2007-03-09       Impact factor: 24.094

8.  Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy.

Authors:  G Cuda; L Fananapazir; W S Zhu; J R Sellers; N D Epstein
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

9.  A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity.

Authors:  R Bottinelli; D A Coviello; C S Redwood; M A Pellegrino; B J Maron; P Spirito; H Watkins; C Reggiani
Journal:  Circ Res       Date:  1998 Jan 9-23       Impact factor: 17.367

10.  Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy.

Authors:  Jenifer G Crilley; Ernest A Boehm; Edward Blair; Bheeshma Rajagopalan; Andrew M Blamire; Peter Styles; William J McKenna; Ingegerd Ostman-Smith; Kieran Clarke; Hugh Watkins
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

View more
  11 in total

1.  Muscle physiology: move to translation.

Authors:  Coen A C Ottenheijm; Richard T Jaspers; Rob C I Wüst; Jolanda van der Velden
Journal:  J Muscle Res Cell Motil       Date:  2014-02       Impact factor: 2.698

2.  Chronic Calmodulin-Kinase II Activation Drives Disease Progression in Mutation-Specific Hypertrophic Cardiomyopathy.

Authors:  Sarah J Lehman; Lauren Tal-Grinspan; Melissa L Lynn; Joshua Strom; Grace E Benitez; Mark E Anderson; Jil C Tardiff
Journal:  Circulation       Date:  2019-03-19       Impact factor: 29.690

Review 3.  Hereditary heart disease: pathophysiology, clinical presentation, and animal models of HCM, RCM, and DCM associated with mutations in cardiac myosin light chains.

Authors:  Sunil Yadav; Yoel H Sitbon; Katarzyna Kazmierczak; Danuta Szczesna-Cordary
Journal:  Pflugers Arch       Date:  2019-01-31       Impact factor: 3.657

Review 4.  Genetics of hypertrophic cardiomyopathy: advances and pitfalls in molecular diagnosis and therapy.

Authors:  Catarina Roma-Rodrigues; Alexandra R Fernandes
Journal:  Appl Clin Genet       Date:  2014-10-03

5.  Novel insights on the relationship between T-tubular defects and contractile dysfunction in a mouse model of hypertrophic cardiomyopathy.

Authors:  C Crocini; C Ferrantini; M Scardigli; R Coppini; L Mazzoni; E Lazzeri; J M Pioner; B Scellini; A Guo; L S Song; P Yan; L M Loew; J Tardiff; C Tesi; F Vanzi; E Cerbai; F S Pavone; L Sacconi; C Poggesi
Journal:  J Mol Cell Cardiol       Date:  2015-12-20       Impact factor: 5.000

6.  Isolation and Mechanical Measurements of Myofibrils from Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Josè Manuel Pioner; Alice W Racca; Jordan M Klaiman; Kai-Chun Yang; Xuan Guan; Lil Pabon; Veronica Muskheli; Rebecca Zaunbrecher; Jesse Macadangdang; Mark Y Jeong; David L Mack; Martin K Childers; Deok-Ho Kim; Chiara Tesi; Corrado Poggesi; Charles E Murry; Michael Regnier
Journal:  Stem Cell Reports       Date:  2016-05-05       Impact factor: 7.765

7.  Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models.

Authors:  Cecilia Ferrantini; Raffaele Coppini; Josè Manuel Pioner; Francesca Gentile; Benedetta Tosi; Luca Mazzoni; Beatrice Scellini; Nicoletta Piroddi; Annunziatina Laurino; Lorenzo Santini; Valentina Spinelli; Leonardo Sacconi; Pieter De Tombe; Rachel Moore; Jil Tardiff; Alessandro Mugelli; Iacopo Olivotto; Elisabetta Cerbai; Chiara Tesi; Corrado Poggesi
Journal:  J Am Heart Assoc       Date:  2017-07-22       Impact factor: 5.501

Review 8.  Cardiomyopathies and Related Changes in Contractility of Human Heart Muscle.

Authors:  Petr G Vikhorev; Natalia N Vikhoreva
Journal:  Int J Mol Sci       Date:  2018-07-31       Impact factor: 5.923

Review 9.  MicroRNAs Based Therapy of Hypertrophic Cardiomyopathy: The Road Traveled So Far.

Authors:  Catarina Roma-Rodrigues; Luís R Raposo; Alexandra R Fernandes
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

10.  Downregulation of GSTK1 Is a Common Mechanism Underlying Hypertrophic Cardiomyopathy.

Authors:  Shota Sasagawa; Yuhei Nishimura; Shiko Okabe; Soichiro Murakami; Yoshifumi Ashikawa; Mizuki Yuge; Koki Kawaguchi; Reiko Kawase; Ryuji Okamoto; Masaaki Ito; Toshio Tanaka
Journal:  Front Pharmacol       Date:  2016-06-14       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.